Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The closing price of Guardant Health Inc (NASDAQ: GH) was $48.87 for the day, up 3.47% from the previous closing price of $47.23. In other words, the price has increased by $3.47 from its previous closing price. On the day, 4.74 million shares were traded. GH stock price reached its highest trading level at $52.92 during the session, while it also had its lowest trading level at $47.1199.
Ratios:
Our analysis of GH’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.36 and its Current Ratio is at 4.68.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Mizuho on April 10, 2025, initiated with a Outperform rating and assigned the stock a target price of $55.
On January 23, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $60.
Guggenheim Upgraded its Neutral to Buy on June 28, 2024, while the target price for the stock was maintained at $36.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 01 ’25 when Talasaz AmirAli bought 340,000 shares for $49.01 per share.
Tariq Musa sold 116 shares of GH for $5,196 on Apr 17 ’25. The Director now owns 3,345 shares after completing the transaction at $44.79 per share. On Apr 17 ’25, another insider, Tariq Musa, who serves as the Director of the company, bought 116 shares for $44.79 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GH now has a Market Capitalization of 6054406656 and an Enterprise Value of 6620782080. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.16. Its current Enterprise Value per Revenue stands at 8.554 whereas that against EBITDA is -16.043.
Stock Price History:
The Beta on a monthly basis for GH is 1.49, which has changed by 1.5884533 over the last 52 weeks, in comparison to a change of 0.092895746 over the same period for the S&P500. Over the past 52 weeks, GH has reached a high of $50.89, while it has fallen to a 52-week low of $17.85. The 50-Day Moving Average of the stock is 11.85%, while the 200-Day Moving Average is calculated to be 41.83%.
Shares Statistics:
GH traded an average of 2.19M shares per day over the past three months and 2401240 shares per day over the past ten days. A total of 123.99M shares are outstanding, with a floating share count of 117.04M. Insiders hold about 5.17% of the company’s shares, while institutions hold 97.71% stake in the company. Shares short for GH as of 1744675200 were 7615429 with a Short Ratio of 3.48, compared to 1741910400 on 8345886. Therefore, it implies a Short% of Shares Outstanding of 7615429 and a Short% of Float of 6.43.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The performance of Guardant Health Inc (GH) in the stock market is under the watchful eye of 14.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.51, with high estimates of -$0.31 and low estimates of -$0.79.
Analysts are recommending an EPS of between -$1.11 and -$3.1 for the fiscal current year, implying an average EPS of -$2.08. EPS for the following year is -$1.76, with 14.0 analysts recommending between -$1.34 and -$2.73.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 17 analysts. It ranges from a high estimate of $219.1M to a low estimate of $202.02M. As of the current estimate, Guardant Health Inc’s year-ago sales were $177.24MFor the next quarter, 17 analysts are estimating revenue of $225.95M. There is a high estimate of $228.9M for the next quarter, whereas the lowest estimate is $218.6M.
A total of 21 analysts have provided revenue estimates for GH’s current fiscal year. The highest revenue estimate was $890.13M, while the lowest revenue estimate was $852.4M, resulting in an average revenue estimate of $879.58M. In the same quarter a year ago, actual revenue was $739.02MBased on 22 analysts’ estimates, the company’s revenue will be $1.07B in the next fiscal year. The high estimate is $1.14B and the low estimate is $1B.
